Short Interest in MetaVia Inc. (NASDAQ:MTVA) Increases By 22.9%

Posted by Geri Gentry on Apr 16th, 2026

MetaVia Inc. (NASDAQ:MTVA – Get Free Report) saw a significant increase in short interest in March. As of March 31st, there was short interest totaling 56,743 shares, an increase of 22.9% from the March 15th total of 46,186 shares. Based on an average daily trading volume, of 181,127 shares, the short-interest ratio is currently 0.3 days. Approximately 1.1% of the company’s stock are sold short.

MetaVia Stock Down 1.4%

MetaVia stock traded down $0.02 during midday trading on Thursday, reaching $1.40. The company’s stock had a trading volume of 39,708 shares, compared to its average volume of 238,543. MetaVia has a fifty-two week low of $1.17 and a fifty-two week high of $19.03. The company has a market cap of $7.13 million, a P/E ratio of -0.17 and a beta of 0.35. The business has a 50-day simple moving average of $1.48 and a 200-day simple moving average of $5.92.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Wall Street Zen upgraded MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, HC Wainwright cut their price target on MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $26.50.

Read Our Latest Research Report on MetaVia

Institutional Trading of MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent filing with the Securities and Exchange Commission (SEC). 1.37% of the stock is currently owned by hedge funds and other institutional investors.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.